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Purpose: Peripheral blood (PB) admixture should beminimized during numerical and functional, as well as cyto-
kinetic analysis of bonemarrow (BM) aspirates for research purposes. Therefore, purity assessment of the BM as-
pirate should be performed in advance. We investigated whether bone matrix vesicle (BMV)-bound bone
alkaline phosphatase (ALP) could serve as a marker for the purity of BM aspirates.
Results: Total ALP activitywas signiﬁcantly higher in BM serum (97 (176–124)U/L,median (range)) compared to
PB serum (63 (52–73) U/L, p b 0.001). Agarose gel electrophoresis showed a unique bone ALP fraction in BM,
which was absent in PB. Native polyacrylamide gel electrophoresis revealed the high molecular weight of this
fraction, corresponding with membrane-bound ALP from bone matrix vesicles (BMV), as evidenced by electron
microscopy. A serial PB admixture experiment of bone cylinder supernatant samples, rich in BMV-bound ALP,
conﬁrmed the sensitivity of this proposed quality assessment method. Furthermore, a BMV ALP fraction of
≥15% is suggested as cut-off value for minimal BM quality. Moreover, the BM purity declines rapidly with larger
aspirated BM volumes.
Conclusion: The exclusive presence of BMV-boundALP in BM could serve as a novelmarker to assess purity of BM
aspirates.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Relatively large amounts of bonemarrow (BM) are aspirated for cellu-
lar analysis and cytokinetic proﬁling of BM inboth diagnostic and research
settings. However, inevitable peripheral blood (PB) contamination during
BM aspiration could lead to misinterpretation of the obtained results. Inlinder; BM, bonemarrow; BMV,
ight; NA, neuraminidase; PAGE,
; PI-PLC, phosphatidyl-inositol-
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. This is an open access article underthe setting of autologous stem cell therapy for cardiovascular diseases
for example, numerical and functional differences between BM could
explain the magnitude of response to stem cell therapy [1], but ideally
should take PB contamination into account. Therefore, quality assessment
of the BMaspirate prior to BManalysis in research settings is essential and
should be reinstated into the ﬁeld [2].
The current method in daily clinical practice to assess purity of a BM
aspirate is a qualitative method based on the observation of spicules in
the BM smear. Quantitative assessment on the other hand is challenging
and is often neglected, and to date, no consensus is reached on an ac-
ceptable gold standard.
A ﬁrst quantitative approach dating from the 80s was based on
the difference of nucleated cells in S-phase index between BM biop-
sies (i.e. bone cylinders) and BM aspirates, which was considered asthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics and indication inwhich cohort the different experiments were per-
formed. The results are expressed as mean ± SD or as percentage (%) of patients.
Characteristic Cohort 1
N = 55
Cohort 2
N = 20
Cohort 3
N = 9
Cohort 4
N = 4
Age (yrs) 63 ± 10 64 ± 11 70 ± 11 42 ± 15
Male (%) 84 90 89 50
BMI (kg/m2) 27 ± 4 27 ± 4 28 ± 3 N.A.
Creatinine clearance
(ml/min)
77 ± 18 74 ± 22 74 ± 20 N.A.
Left ventricular ejection
fraction (%)
53 ± 19 52 ± 18 44 ± 12 N.A.
Framingham risk score (%) 14 ± 8 15 ± 8 19 ± 10 N.A.
CRP (mg/l) 5.7 ± 7.8 15.1 ± 33.3 27.7 ± 46.3 N.A.
Diabetes (%) 5 5 22 N.A.
Pulmonary disease (%) 9 3 22 N.A.
Surgery
- CABG (%) 71 68 67 N.A.
- Aortic valve surgery (%) 7 11 33 N.A.
- Mitral valve surgery (%) 24 11 0 N.A.
- VAD implantation (%) 7 5 0 N.A.
- Heart transplantation (%) 2 5 0 N.A.
Medication
- Statins (%) 66 63 44 N.A.
- B-blockers (%) 64 68 89 N.A.
- ACE-inhibitors (%) 31 21 33 N.A.
- Diuretics (%) 35 37 33 N.A.
Total aspirated BM
volume (ml)
10 10 20 N.A.
Sampled arterial PB
volume (ml)
10 10 10 N.A.
Experiment
- Total ALP activity
quantiﬁcation
X
- ALP isoenzymes/isoforms
differentiation
X
- MW ALP isoforms
determination
X
- In vitro PB admixture
experiment of BC SN
X
- BMV ALP versus Holdrinet
comparison
X
- Inﬂuence of aspirated BM
volume on BMV ALP
X
Abbreviations: ALP, alkaline phosphatase; ACE-inhibitors, angiotensin-converting-en-
zyme inhibitors; BC SN, bone cylinder supernatant; BM, bone marrow; BMI, body mass
index; BMV, bone matrix vesicle; CABG, coronary artery bypass grafting; CRP, C-reactive
protein; VAD, ventricular assist device.
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ﬂow cytometric quantiﬁcation of the percentage CD45+gated lympho-
cytes andmonocytes in the BM aspirate was introduced to evaluate BM
quality, since this percentage is inversely related to the percentage of
cells in the S-phase for the total BM cell population [4]. A total lympho-
cyte–monocyte count of N30% was used as cut-off value to exclude BM
aspirates with an unacceptable degree of PB contamination [4]. Nowa-
days, the most common technique is the Holdrinet method [5,6]. By
means of Cr15 labeled autologous erythrocytes, Holdrinet et al. showed
that 97% of the hemoglobin (Hb) content in BM is derived from PB.
Based on the assumption that a proportional number of PB cells is pres-
ent, the fraction of PB admixture could be calculated by determining the
Hb levels in blood and bone marrow.
However, the aforementioned methods for the quantiﬁcation of PB
admixture to BM aspirates are based on cellular assessments and should
not be used in conditions that possibly inﬂuence cellular function of BM
such as heart failure [7–9]. Therefore, we searched for an alternative sta-
ble marker, which is exclusively present in BM and is independent of
BM cellular characteristics.
To this purposewe investigated bone alkaline phosphatase (ALP), an
important bone turnovermarker produced by bone forming osteoblasts
from BM [10]. The enzyme ALP consists of different isoenzymes and, in
humans, four ALP genes are identiﬁed: tissue-nonspeciﬁc, intestinal,
placental and germ-cell ALP [11,12]. After posttranslational modiﬁca-
tions of the tissue-nonspeciﬁc ALP gene product, bone and liver ALP iso-
forms are formed [11].
Whereas the tertiary structure of ALP in PB promotes dimerization,
tetrameric ALP and high molecular weight (MW) isoforms have also
been described for all the ALP isoenzymes/isoforms [11]. The high
MW isoforms consist of ALP anchored to the plasma membranes of
shedded microvesicles and incubation of these microvesicles with a
non-ionic detergent results in the release of anchor-bearing ALP from
the membrane which, in the presence of detergents, has a MW that is
consistent with tetrameric ALP [11]. Phospholipases, such as
phosphatidyl-inositol-speciﬁc phospholipases, are responsible for the
conversion of this tetrameric ALP into the soluble dimeric form of ALP
[11,13–15].
In PB serum from healthy subjects, liver and bone ALP mainly circu-
late as soluble dimers, and tetrameric liver and bone ALP are absent. In
pathological conditions, theﬁnding ofmembrane-boundboneALP in PB
is extremely rare, in contrast to membrane-bound liver ALP [11].
We hypothesized that a high activity ofmembrane-bound bone ALP,
originating from bone matrix vesicles (BMV) formed by budding of os-
teoblasts that reside in theBM [16], is present in BMaspirates but absent
in PB. As such, the activity of BMV-bound ALP could serve as a novel
marker to assess BM purity.
2. Materials and methods
2.1. Patients and collection of BM and PB samples
After approval of the Antwerp University Hospital Ethics Committee
andwritten informed consent, patients undergoing elective cardiac sur-
gery were included in the study. Exclusion criteria were chronic inﬂam-
matory or malignant disease, chronic kidney disease (Creatinine
clearance b30ml/min), severe liver failure and disorders with abnormal
bone turnover. Table 1 shows the patient characteristics and indicates
in which cohort the experiments were performed.
Prior to sternotomy and under general anesthesia, BM sampleswere
aspirated by sternal puncture (15G Jamshidi BM aspiration needle) as
described previously [17] and arterial PB was sampled. Both BM and
PB were collected in Vacutainer® serum tubes (Becton Dickinson (BD)
Benelux, Erembodegem, Belgium). Serum of BM and PB was obtained
by 15 minute centrifugation at 1500 g. For the quantiﬁcation of PB ad-
mixture by the Holdrinet method, PB and BM samples were collected
in Vacutainer® EDTA tubes (BD Benelux) to determine Hb levels.2.2. Quantiﬁcation of total ALP activity
Total ALP activity (U/L) of BM and PB serum was measured spec-
trophotometrically on the Dimension Vista® System (Siemens),
using the ALP Flex® reagent cartridge (Siemens). This colorimetric
assay uses p-nitrophenylphosphate (p-NNP) as substrate, which is
catalyzed into p-nitrophenol (p-NP) by all ALP isoenzymes/isoforms.
For this IFCC calibrated method, the reference interval for healthy indi-
viduals in PB serum is 42–98 U/L inwomen from 15 to 59 years old, 53–
141 U/L for women older than 59 years, 53–128 U/L in men from 20 to
59 years old and 56–119 U/L for men older than 59 years [18,19]. Coef-
ﬁcients of variation for total ALP activity quantiﬁcation were 4.5% for a
mean ALP activity of 27 U/L (n = 86 PB serum samples) and 2.7% for a
mean activity of 137 U/L (n = 85 PB serum samples).2.3. ALP isoenzyme/isoform differentiation
To separate the different ALP isoenzymes and isoforms present in PB
and BM serum, agarose gel electrophoresis was performed with the
Isopal Plus® kit (Beckman Europe, Analis S.A, Suarlée, Belgium) as de-
scribed previously [20]. In addition, samples were subjected to a set of
treatments for ALP isoenzyme differentiation. Treatment with neur-
aminidase (2 U/ml, puriﬁed from Clostridium perfringens, Analis S.A.)
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a different degree of sialylation [21,22]. By incubating the samples at
56 °C for 10 min, bone ALP will be inhibited by heat inactivation,
while liver ALP is less sensitive to heat treatment. PI-PLC (≥200 U/mg,
puriﬁed from Bacillus cereus, Sigma-Aldrich) treatment is responsible
for the in vitro dissociation of tetrameric ALP into dimeric ALP [13].
For the detection of intestinal and placental ALP, a single
DAKOCytomation polyclonal placental ALP antibody that binds both iso-
enzymes was used (3 g/l, a puriﬁed immunoglobulin fraction of rabbit
antiserum in 0.1 mol/l NaCl and 15mmol/l NaN3, Analis S.A.). A positive
control for BMV ALP consisted of supernatant (SN) of a bone cylinder
(BC) from the vertebra, collected from 1 organ donor at the time of
organ prelevation (see Supplementary methods).
2.4. Quantiﬁcation of ALP isoenzyme/isoform activity
To quantify the activity of the different ALP isoenzymes and iso-
forms, gels were scanned at 600 nm in a densitometer (Appraise,
Beckman Instruments Inc.). The ALP isoenzyme activity was expressed
in U/L and as a percentage of total ALP activity.
2.5. Estimation of MW for different ALP isoforms
Native polyacrylamide gel electrophoresis (PAGE) was per-
formed to separate the different MW isoforms of ALP (see Supple-
mentary methods). For the MW estimation of the ALP isoforms, a
protein standard was loaded onto the gel. After electrophoresis,
this protein standard was cut off and stained with Coomassie blue,
followed by overnight destaining. The other part of the gel was incu-
bated for 30 min at 45 °C with the ALP-substrate 5-bromo-4-chloro-
3-indolyl phosphate (Analis S.A.) in order to visualize the ALP activ-
ity. BM and PB serum samples were also treated with the non-ionic
detergent n-butanol (pH 8–8.5) [13].
2.6. Visualization of bone matrix vesicles (BMV)
Transmission electron microscopy (TEM) was used for direct visual-
ization of BMV in BM and PB serum. After puriﬁcation of high-MW ALP
on the polyacryamide gel, high-MW bands of untreated PB and BM
serum were cut out of the gel. The bands were ﬁxed in 0.1 M sodium
cacodylate-buffered (pH 7.4) 2.5% glutaraldehyde solution for 2 h at
room temperature, and then washed three times in 0.1 M sodium
cacodylate-buffered (pH 7.4) 7.5% saccharose solution. Post-ﬁxation
was performed by incubating cells for 2 h with 1% OsO4 solution. After
dehydration, the samples were embedded in EM-bed812. Ultrathin sec-
tionswere stainedwith uranyl acetate and lead citrate, and examined in
a Tecnai G2 Spirit Bio TWIN microscope (Fei, Europe BV, Zaventem,
Belgium) at 120 kV.
2.7. In vitro admixture of BC SN with PB serum
Bone cylinders (BC) from the vertebra were collected from 4 de-
ceased heart-beating organ donors at the time of organ prelevation,
whichwas approved by the Antwerp University Hospital Ethics Commit-
tee. Spongiosa BC were softly shaken overnight in 1 ml saline in order to
isolate the BMV. For each donor, 5 of the obtained BC supernatant (BC
SN) samples, which were rich of BMV, were pooled and ﬁltered prior
to further analysis. Total ALP activity and the electrophoretic isoenzyme
pattern of the BC SN were evaluated as described in Sections 2.2.–2.4.
These BC SN samples were used for the setup of an in vitro addition ex-
periment of BC SNwith PB serum in different degrees (0–20–40–60–80–
100%). For each percentage admixture, total ALP activity as well as the
percentage of BMV ALP was determined. This addition experiment was
performed on the pooled BC SN sample of each donor.2.8. Correlation between BMV ALP % in BMand PB admixture % in BMquan-
tiﬁed by Holdrinet
In order to ascertain if there is a correlation between the measured
BMVALP percentage in BM and the PB admixture degree to the BM aspi-
rate quantiﬁed according to the previously proposed Holdrinet method
[5], theHb content and number of nucleated cells in BMand PB, collected
in EDTA tubes, were measured on the Sysmex Automated Hematology
Analyzer XS-1000i (Sysmex). The PB admixture of each BM aspirate ac-
cording to Holdrinet et al. was calculated using the following formula:
percent nucleated PB cells = (Hb BM asp / Hb PB) × (nucleated cells
PB / nucleated cells BM asp) × 100.
2.9. BMV ALP measurement in different aspirated BM volumes
To investigate whether the PB admixture increases with larger aspi-
rated BM volumina, BMwas aspirated in a fractionated way. In each pa-
tient 2, 3, 5, 5 and 5 ml BM was aspirated successively in different
syringes without replacing the Jamshidi BM aspiration needle. Total
ALP activity and different ALP isoenzyme/isoform at each stage were
compared to the ﬁrst aspirated 2 ml BM.
2.10. Statistical analysis
Results are expressed as median (interquartile range—IQR). IBM
SPSS Statistics version 22.0 was used for statistical analysis. A p-
value b 0.05was considered statistically signiﬁcant. The comparison be-
tween total ALP activity in PB and BM serumwasmade by theWilcoxon
signed rank test. Differences in BMV ALP fraction between the different
aspirated BM volumes were calculated using the Friedman test, follow-
ed by a pairwise comparison by theWilcoxon signed rank test. The cor-
relation between themeasured BMVALP fraction and the PB admixture
to the BM aspirate quantiﬁed according to the Holdrinet method was
evaluated by the Spearman test. Multivariate regression analysis was
performed for the determination of independent predictors of BMV-
ALP percentage.
3. Results
3.1. Quantiﬁcation of total ALP activity
Total ALP activity was measured in BM and PB serum samples in 55
patients undergoing cardiac surgery (Table 1, cohort 1). Total ALP activ-
ity was signiﬁcantly higher in BM serum (97 (176–124) U/L) compared
to PB serum (63 (52–73) U/L, p b 0.001).
3.2. ALP isoenzyme/isoform separation and quantiﬁcation in PB and BM
samples
When comparing the electrophoretic pattern of untreatedBMserum
with the pattern of untreated PB serum, a distinct fraction with a more
anodal migration was detected exclusively in BM serum (Fig. 1). This
fraction was identiﬁed as bone type ALP based on neuraminidase treat-
ment (a clear separation between bone and liver ALP occurred) and in-
cubation of BM serum at 56 °C during 10 min (the bone ALP fraction
disappeared). In other words, BM serum contains a unique bone ALP
fraction, which is absent in PB serum. One sample of bone cylinder su-
pernatant (BC SN) with a total ALP activity of 217 U/L of 1 organ
donor was used twice as positive control for bone samples without PB
admixture. The samples mainly consisted of the same unique bone
ALP fraction that was encountered in BM aspirates, without any detec-
tion of liver ALP. Based on these results we hypothesized that this
unique bone ALP fraction was high-MW bone ALP.
Quantiﬁcation of the activity of the ALP isoenzymes/isoforms was
performed in both BM and PB serum. A representative example of a
densitometer scan is presented in Supplementary Fig. 1. Table 2 shows
Fig. 1. Agarose gel electrophoresis of alkaline phosphatase (ALP) in peripheral blood (PB) serum, bonemarrow (BM) serum and bone cylinder supernatant (BC SN). Untreated PB serum
(total ALP of 71 U/L, lane 1); untreated BM serum (total ALP of 113 U/L, lane 2); BM serum after treatment with neuraminidase (NA; lane 3), BM serum after treatment with NA and heat
inactivation by incubation at 56 °C during 10min (lane 4); untreated BC SN (total ALP of 217 U/L, positive control, lane 5 and 8); BC SN after treatment NA (lane 6 and 9); and BC SN after
treatment with NA and heat inactivation (lane 7 and 10). BM serum contains a unique high-molecular weight (MW) bone ALP fraction, which is absent in PB serum.
256 E. Nollet et al. / Clinica Chimica Acta 446 (2015) 253–260the percentages of the different ALP isoenzymes/isoforms in BM and PB
serum of the ﬁrst cohort of 55 patients. The high-MWbone ALP fraction
was detected in BM of all patients and represented 25% (15–43%) of
total ALP. In contrast, this fraction was completely absent in all PB
serum samples. Next to high-MW bone, bone and liver ALP, also a very
small high-MW liver ALP fraction was detected in BM in only 6 out of
55 patients. Intestinal ALP was never detected in BM, but 8 out of 55 pa-
tients contained a very small intestinal ALP fraction in PB. The intra-assay
coefﬁcient of variation for the quantiﬁcation of high-MW bone ALP with
mean ALP activity of 56.7 U/L in a BM serum sample was 7.12% (10mea-
surements). The inter-assay coefﬁcient of variationwas 15.3% for amean
bone ALP activity of 19 U/L (n = 14 PB serum samples) and 9.5% for a
mean liver ALP activity of 50 U/L (n = 14 PB serum samples).
The unique high-MWbone ALP fraction showed a rather wide range
in our cohort (IQR15–43%,minimum5%,maximum83%). Therefore, we
performed multivariate regression analysis for the detection of inde-
pendent determinants for this high-MW bone ALP fraction. Clinical var-
iables, such as left ventricular ejection fraction, Framingham risk score
(i.e. 10-year cardiovascular disease risk), CRP, renal function as well as
age and medication were included in the analysis, however, no signiﬁ-
cant determinants were detected.Table 2
Percentages of the ALP isoenzymes/isoforms present in BM aspirates and PB serum of 55
patients. The presence of a unique high-MWboneALP fractionwas conﬁrmed in all 55 pa-
tients and expressed as a percentage of the total ALP activitymeasured in BMor PB serum.
Results are expressed as median (IQR).
ALP isoenzyme/isoform % of total ALP activity BM PB
Bone ALP 23.1 (13.8–31.7) 29.2 (22.8–37.3)
High-MW bone ALP (BMV ALP) 25.0 (15.2–42.8) 0 (0–0)
Liver ALP 46.9 (31.5–58.5) 64.1 (58.3–73.6)
High-MW liver ALP 0 (0–0) 2.8 (0–4.6)
Intestinal ALP 0 (0–0) 0 (0–0)
Abbreviations: ALP, alkaline phosphatase; BM, bone marrow, BMV, bone matrix vesicles;
MW, molecular weight; PB, peripheral blood.3.3. Identiﬁcation of different MW ALP isoforms
The native PAGE experiment (Fig. 2) shows that the high-MW ALP
isoforms (N1236 kDa) were predominantly present in the untreated
BM serumas compared to the untreated PB serum.Heat-inactivation re-
sulted in a signiﬁcant reduction in ALP activity of the high-MW isoforms
in BM serum, but not in PB serum. This observation conﬁrmed that the
high-MW ALP isoforms in BM serum correspond with bone type ALP
and those in PB serum with liver type ALP.
ALP in PB serum is mainly present in its dimeric form (estimated
MW 242 kDa), while ALP in BM serum is mainly present in the high-
MW form. N-butanol treatment of BM serum resulted in the release
from the high-MW fraction of ALP with an estimated MW of 480 kDa,
hence this fraction is called ‘tetrameric’ ALP [11,13]. This tetrameric
ALP was also heat-sensitive, proving its bone origin. Since no 480 kDa
protein band is visible in PB serum, we conﬁrmed previous ﬁndings
that in normal conditions no tetrameric ALP is found in PB serum from
healthy adults [11].
Treatment with PI-PLC of PB serum and BM serum showed a reduc-
tion of the ALP activity at the level of high-MW bone type isoforms and
BM serum also showed a smear between the molecular weights of tet-
rameric and dimeric ALP, which is in line with the ﬁnding of Hawrylak
et al. [13] that PI-PLC is responsible for the dissociation of tetrameric
ALP into dimeric ALP. In conclusion, native PAGE revealed that the
unique ALP fraction found in BM serum is indeed a high-MW bone
type ALP.3.4. Visualization of BMV in high-MW PAGE bands of BM
To determine whether the high-MW bone ALP fraction in BM corre-
sponds with BMV-bound ALP, TEM of the high-MW PAGE bands of BM
was performed. Indeed, TEM images showed the presence of BMV
(Fig. 3), which were identiﬁed based on their properties as described
previously by Golub et al. [16]. The vesicles had a size of 20–200 nm
Fig. 2. Separation of the different molecular weight (MW) isoforms of bone and liver ALP in
PB andBMserum.With n-butanol treatment: PB serum(1); PB serumafter heat-inactivation
(2); PB serum after PI-PLC (phosphatidyl-inositol-phospholipase C) treatment (3); PB
serum after heat-inactivation and PI-PLC treatment (4); BM serum (5); BM serum after
heat-inactivation (6); BMserumafter PI-PLC treatment (7); BMserumafterheat-inactivation
and PI-PLC treatment (8).Without n-butanol treatment: PB serum(10); PB serumafter heat-
inactivation (11); BM serum (12); BM serum after heat-inactivation (13).
257E. Nollet et al. / Clinica Chimica Acta 446 (2015) 253–260with a phospholipid bilayer membrane. Henceforth, the unique high-
MW bone ALP fraction present in BM serum will be called bone matrix
vesicle-bound ALP (BMV-ALP).
3.5. In vitro admixture of BC supernatant with PB serum
Total ALP activity of the bone cylinder supernatant (BC SN) samples
of 4 different organ donors was 394 (252–765) U/L. The BMV ALPFig. 3. Bonematrix vesicles (BMV) visualized inBMbyTEMafter puriﬁcation onPAGE. The bonemfraction accounted for 87 (81–98) % of the total ALP activity in these
samples, the remaining ALP activity was due to the presence of dimeric
bone ALP.
Serial dilution of the pooled BC SN samples with PB serum of a
healthy subject (total ALP activity of 71 U/L)was performed. The results
of the 4 admixture experiments are summarized in Supplementary
Fig. 2. This PB admixture experiment to BC SN samples demonstrates
that the measured BMV ALP fraction (%) diminishes with increasing
PB admixture (%) and conﬁrms that the established BMV ALP technique
is sensitive for the detection of PB admixture to BM aspirates.
3.6. Correlation between BMV ALP and the Holdrinet method for quality as-
sessment of BM aspirates.
In a second cohort of 20 patients (Table 1), the BMVALP fractionwas
similar to the ﬁrst cohort with a median fraction of 30% (14–64%). Fur-
thermore, the degree of PB admixture of these BM aspirates quantiﬁed
by the Holdrinet method was 23 (14–43) %. A signiﬁcant, although
weak correlation was found between BMV ALP % and PB admixture %
quantiﬁed by the Holdrinet method (r =−0.496; p = 0.026).
3.7. BMV ALP measurement in ascending aspirated BM volumes
Not only total ALP activity, but also the fraction of BMV ALP de-
creases signiﬁcantly with increasing aspirated BM volume, as shown
in Figs. 4a and b respectively. For every BM aspirate, the ﬁrst 2 ml con-
tains the highest total ALP activity (146 (107–213) U/L) and highest
BMV ALP percentage (37 (14–54) %). The decrease in BMV ALP % is sig-
niﬁcant when aspirating 10 ml BM or more compared to the ﬁrst aspi-
rated 2 ml BM. These results show that the purity of BM aspirates
decreases with increasing aspirated BM volume.
Fig. 4c shows BMVALP and liver ALP in BMaspirates. The presence of
liver ALP is considered to be a result of PB admixture. As expected, there
is an inverse correlation between liver ALP % and BMV ALP % in BM
(r =−0.608, p b 0.001). In other words, the presence of liver ALP in-
creaseswith decreasing purity of the BMaspirate and thus, alsowith in-
creasing aspirated BMvolume.Whenmore than 3ml of BM is aspirated,
liver ALP becomes more abundantly present than BMV ALP.
3.8. Determination of minimal BM quality
A gold standard for 100% pure BM is needed in order to calculate the
percentage of PB admixture to the aspirate by means of BMV ALP %. BC
SN is very rich in BMVALP, but as it is directly derived from bone it can-
not be used as gold standard for BM. Neither can the ﬁrst 2 ml BM of an
aspirate be used as, although this is the most pure BM that we can ob-
tain, even this small quantity of aspirate still shows a large variation in
BMV ALP % between patients.atrix vesicles have a size of 20–200nmwith aphospholipid bilayermembrane (black arrow).
Fig. 4. A–C: Analysis of total ALP activity, BMV ALP and liver ALP in ascending aspirated BM volumes. A. Total ALP activity (U/L) and B. BMV ALP (%)were quantiﬁed in the ﬁrst 2, 5, 10, 15
and 20 ml BM of the total aspirated BM volume (20 ml) of 9 patients. Both total ALP activity and BMV ALP decrease signiﬁcantly (Friedman; p = 0.001 and p= 0.010 respectively) with
increasing aspirated BM volume. The decrease in BMV ALP fraction is signiﬁcant (p b 0.05) when aspirating 10ml BM or more compared to the ﬁrst 2 ml aspirated BM. C. In contrast, the
percentage of liver ALP in BM increases with increasing aspirated BM volume.
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the BMV ALP %. As minimum BMV ALP % we suggest the ﬁrst quartile
value of the measured BMV ALP % that was determined in a cohort of
55 patients (Table 1, cohort 1), i.e. 15%. As such, we suggest rejecting
BM aspirates with a BMV ALP % ≤ 15% for further analysis.
4. Discussion
In the present study, we investigated whether bone matrix vesicle
(BMV)-bound bone alkaline phosphatase (ALP) could serve as a marker
for the purity of bonemarrow aspirates. Several ﬁndings emerged from
this study. Firstly, we demonstrated by electrophoresis that bone mar-
row (BM) contains a unique bone ALP fraction, with a high molecular
weight, which is absent in peripheral blood (PB). Electron microscopy
showed ample presence of BMV, which strongly suggests that the
unique high-HW bone ALP fraction corresponds to membrane-bound
bone ALP originating from BMV. Due to its exclusivity to the bone mar-
row, BMV-bound ALP could serve as a novel marker to assess the purity
of BM aspirates. Furthermore, serial dilution with PB of bone cylinder
supernatant, containing high levels of BMV ALP, demonstrated well
how the BMV ALP fraction decreases with increasing PB admixture,
proving the sensitivity of this proposed quality assessment method. In
addition, purity of BM aspirates declines rapidly when larger volumes
are aspirated.
4.1. Comparison between BMV ALP and the Holdrinet method for assessing
the degree of PB admixture in BM aspirates
As a consequence of inevitable PB admixture to BM aspirates [23],
quality assessment of the BMaspirate is essential in order to prevent un-
reliable results during numerical, functional and cytokinetic analyses of
BM aspirates for research and diagnostic purposes. Although a goldstandard for quantiﬁcation of PB admixture to BM aspirates is still lack-
ing, a fewmethods have been proposed previously, such as the ﬂow cy-
tometric quantiﬁcation of lymphocytes and monocytes in BM [4] and
themethod by Holdrinet et al., [5] which is based on the ratio of the he-
moglobin (Hb) content in BM compared to PB. These methods are deﬁ-
nitely of value in some conditions. However, since the number of
nucleated PB cells in BM can be inﬂuenced by pathophysiological condi-
tions associated with cellular BM dysfunction, the application of these 2
methods is hampered in these conditions [7].
Therefore, identiﬁcation of a stablemarker, that is exclusively present
in BM and is independent of BM cellular characteristics is mandatory.
Comparison between the proposed BMV ALP fraction and the
Holdrinet method revealed a signiﬁcant, although weak correlation.
However, all patients in this study had overt cardiovascular disease,
which could have been associated to a potential BM dysfunction and
hence, incorrect interpretation when using the Holdrinet method [9].4.2. Variation in BMV ALP between patients
The measured BMV ALP fraction in BM from 55 cardiovascular
patients without underlying bone disorder, showed a wide range of
BMV-ALP (15–43%, IQR). However, comprehensive multivariate analy-
siswith several clinical and patient characteristics could not identify im-
portant determinants for the level of BMVALP. In addition, we could not
detect a signiﬁcant inﬂuence of the intake of cardiovascular medication
on BMV ALP levels. This is in agreement with previous studies on beta-
blockers [24] andACE-inhibitors [25], inwhich no effectwas seen of this
medication on bone type ALP activity. However, concerning statin use,
Stein et al. observed that in vitro treatment of serum with statins de-
creases the bone ALP levels in serum samples [26]. In contrast, the ALP
activity is signiﬁcantly enhanced by statin treatment in bone tissue
[27,28]. Yet, we entered statin use, which was taken by 66% of the
259E. Nollet et al. / Clinica Chimica Acta 446 (2015) 253–260patients, as variable in the statistical analysis, but no inﬂuence of statins
on BMV ALP levels could be detected.4.3. Molecular weight determination of the different ALP isoenzymes/
isoforms
As mentioned, MWs were estimated by native gradient PAGE. Our
results are in agreementwith previous reports, wherein TNALP released
by a nonionic detergent from membrane-bound bone ALP in cultured
human osteosarcoma cells (SAOS-2 cells) [29], or membrane-bound
liver ALP from human liver cells [13], had a MWof 440 and 445 kDa re-
spectively. In these studies, the estimated MW of dimeric bone ALP or
dimeric liver ALP released by PI-PLC was 200 and 214 kDa respectively.
There are, however, discrepancies between these MW estimates and
those obtained by native gradient gels in other publications [30–33].
This holds true especially for the dimers, with estimated MWs in these
reports ranging from 130 to 150 kDa, which is more in agreement
with the theoretical MW (108 kDa) calculated from the known amino
acid sequence for tissue-nonspeciﬁc ALP. Differences in hydrophobicity
and/or oligosaccharide content between boneALPproduced by cultured
SAOS-2 osteosarcoma cells, and bone ALP produced by native (non-cul-
tured) non-malignant osteoblasts might account for the observed
discrepancies.
Although the main circulating ALP fractions are dimeric and hydro-
philic, we have demonstrated previously by means of gel electrophore-
sis, gel chromatography and 2D electrophoresis that hydrophobic,
heterogeneous forms of bone, liver, intestinal and placental ALP can cir-
culate in human serum [11,34,35]. Because of the hydrophobic nature of
these fractions, we concluded that they retained at least part of their GPI
anchor. In the presence of detergents, their MW could be estimated to
be approximately 400 kDa, hence they were called ‘tetrameric’ ALP.
We hypothesize that the two dimers are held together by interactions
between the hydrophobic tails, as the enzyme takes on a dimeric struc-
ture when the GPI-anchor is lost, and as no obvious surface domain that
could be involved in tetramer formation could be demonstrated in the
3D-structure of human ALP [36].4.4. Aspirated BM volume and minimal quality cut-off value for BM purity
Quality assessment by means of BMV ALP determination with as-
cending aspirated BMvolume conﬁrmed thehypothesis that theBMpu-
rity decreases by increasing aspirated BMvolume,which implicates that
only theminimum needed BM volume should be aspirated and that the
complete aspirated BM volume should be well mixed prior to BM anal-
ysis experiments. Moreover, when aspirating more than 3 ml BM, liver
ALP becomes more abundantly present in BM compared to BMV ALP.
Therefore, we suggest that a maximum of 3 ml BM should be aspirated
when high quality BM is required for further analysis.
Additionally, since a gold standard for 100% pure BM in order to cal-
culate the percentage of PB admixture by means of BMV ALP % is still
lacking, we suggest a minimum purity for a BM aspirate, based on the
BMV ALP %. The ﬁrst quartile value of the measured BMV ALP fractions
in a cohort of 55 patients, which is currently the largest cohort that is
available in literature, was suggested as cut-off value, i.e. ≥15%. Obvi-
ously, this percentage can be re-considered, as more measurements
will be performed in the future by different research groups and using
different techniques.
Furthermore, we recommend the use of the proposed BMV ALP
based quality assessment of BM aspirates for research purposes rather
than for daily practice. Due to its labor intensity, the method is less ap-
plicable as a routinemethod for the conventional cytogenetic analysis of
BM for diagnosis and prognosis of hematological disease, where also
only a minimal volume of BM is aspirated, in contrast to the higher
BM volumes (20 ml) needed for research purposes.4.5. Technical aspects taken into account during ALP quantiﬁcation
We previously showed that ALP activity in healthy adult non-
pregnant subjects is quite constant [11]. However, since lower total
ALP levels have beenmeasured in patients after cardiac surgery, it is im-
portant to sample blood prior to sternotomy [37]. Furthermore, we used
BM and PB serum instead of EDTA or heparin plasma during the ALP ex-
periments, since EDTA inhibits ALP activity [18] and heparin causes rup-
tures in the agarose gel. In contrast, for themeasurements necessary for
the PB admixture quantiﬁcation in BM aspirates using the Holdrinet
method, the collection of BM in EDTA tubes was required.
In addition, several liver diseases are responsible for elevated ALP
levels in PB [11]. Since the presence of liver ALP in BM is completely
due to PB admixture, high liver ALP activity in PB could lead to a lower
percentage of BMV-bound ALP in BM, resulting in a false elevated esti-
mation of PB admixture. In these cases the use of the suggestedmethod
is hampered. Elevated bone ALP activity on the other hand, will not in-
ﬂuence the relative percentage of BMV-bound ALP in BM, since bone
ALP activity in PB reﬂects the bone ALP activity in BM.
5. Conclusion
The developed technique for quality assessment of BM aspirates is
based on the presence of a unique BMV-bound bone ALP fraction in
BM. To our knowledge, this is the ﬁrst report of the presence of BMV-
bound ALP in human BM aspirates. Since total ALP activity and the
ALP isoenzyme pattern are signiﬁcantly different in BM as compared
to PB, thesemarkers can serve to assess PB admixture to BMsamples, in-
dependently of hematological indices. Furthermore, aminimal BMVALP
fraction of 15% of total ALP activity in BM aspirates is suggested as cut-
off value. Lastly, the purity of BM aspirates is inversely correlated with
the aspirated BM volume.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2015.04.013.
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